Bleeding Disorders Testing Market Size to Achieve USD 192 Million by 2033, Fueled by a CAGR of 7.8%

Bleeding Disorders Testing Market to Reach $192.0 Million, Globally, by 2033 at 7.8% CAGR: Allied Market Research

PORTLAND, OR, UNITED STATES, November 21, 2024 /EINPresswire.com/ -- The bleeding disorders testing market is driven by rising prevalence of bleeding disorders, increasing awareness and early diagnosis, advancements in testing technologies, and growing healthcare expenditure. Additionally, supportive government initiatives and expanding applications of these tests further boost market growth.

Allied Market Research published a report, titled, "Bleeding Disorders Testing Market by Product (Reagents and Consumables and Instruments), Indication (Hemophilia A, Hemophilia B, Von Willebrand Disease and Others), and End User (Hospitals and Clinics, Diagnostic Centers and Others): Global Opportunity Analysis and Industry Forecast, 2024-2033". According to the report, the bleeding disorders testing market was valued at $90.9 million in 2023, and is estimated to reach $192.0 million by 2033, growing at a CAGR of 7.8% from 2024 to 2033.

𝐆𝐞𝐭 𝐒𝐚𝐦𝐩𝐥𝐞 𝐏𝐃𝐅 𝐑𝐞𝐩𝐨𝐫𝐭 𝐰𝐢𝐭𝐡 𝐆𝐫𝐚𝐩𝐡𝐬 𝐚𝐧𝐝 𝐅𝐢𝐠𝐮𝐫𝐞𝐬 𝐇𝐞𝐫𝐞: https://www.alliedmarketresearch.com/request-sample/A323977

Prime determinants of growth

The bleeding disorders testing market is driven by several key factors. The increasing prevalence of bleeding disorders such as hemophilia, von Willebrand disease, and other clotting factor deficiencies significantly boosts demand. Advances in diagnostic technologies, including next-generation sequencing and point-of-care testing, enhance early and accurate diagnosis, further propelling market growth. Growing awareness and improved healthcare infrastructure in emerging economies also contribute to market expansion. Additionally, favorable government initiatives and funding for research and development in bleeding disorder diagnostics play a crucial role in driving the market forward. Top of Form

Segment Highlights

Increase in adoption of reagent and consumables in bleeding disorders diagnostics

Reagents and consumables are essential components used in various diagnostic tests and procedures, making them indispensable for routine and specialized testing. Their widespread use across a range of diagnostic assays contributes to their significant market share. Additionally, the recurrent nature of their use in ongoing patient monitoring and testing drives consistent demand. The relatively lower cost compared to diagnostic instruments also makes reagents and consumables more accessible and frequently purchased. As a result, this segment maintains a substantial share of the market due to its fundamental role in the accurate and efficient diagnosis of bleeding disorders.

Increase in prevalence of Hemophilia A

Hemophilia A, the most common type of hemophilia, affects a significant portion of the population, creating substantial demand for diagnostic testing. The condition is characterized by a deficiency in clotting factor VIII, which requires ongoing monitoring and management. This high prevalence drives extensive use of diagnostic tests specifically designed for Hemophilia A. Additionally, advancements in diagnostic technologies and increased awareness about Hemophilia A contribute to its dominant market position. The comprehensive range of available tests for Hemophilia A, coupled with its critical role in patient management and treatment planning, further reinforces its status as the largest segment.

The Availability of Advanced Diagnostic Tools and Technologies in Hospitals

Hospitals and clinics are equipped with advanced diagnostic tools and technologies essential for accurately identifying and managing bleeding disorders, such as hemophilia and von Willebrand disease. Additionally, the frequent need for immediate and comprehensive diagnostic services in these settings drives the demand for bleeding disorder tests. Hospitals and clinics often serve as the primary point of care for patients requiring specialized tests, further solidifying their position as the largest segment in this market. Their extensive infrastructure and ability to provide continuous care enhance their role as key players in the bleeding disorders testing industry.

Regional Outlook

North America to maintain its dominance by 2033

By region, North America held the largest market share in terms of revenue in 2023 and is expected to dominate the market during the forecast period. This is attributed advanced healthcare infrastructure and high healthcare expenditure, which support the adoption of cutting-edge diagnostic technologies. The presence of leading market players and research institutions further accelerates innovation and development in diagnostic tools. Additionally, strong government support through funding and initiatives aimed at improving healthcare for bleeding disorders contributes significantly to market dominance. High levels of awareness and education about bleeding disorders also drive demand for accurate and timely diagnostic solutions. Together, these factors position North America as a leading region in the market, with continued growth anticipated throughout the forecast period.

Top Key Players: -

• Siemens Healthineers
• Abbott Laboratories
• Roche Diagnostics
• Bio-Rad Laboratories, Inc.
• Sysmex Corporation
• Thermo Fisher Scientific Inc.
• Grifols S.A.
• Danaher Corporation
• Siemens AG
• Novo Nordisk A/S

The report provides a detailed analysis of these key players in the global bleeding disorders testing market. These players have adopted different strategies such as new product launches, collaborations, expansion, joint ventures, agreements, and others to increase their market share and maintain dominant shares in different regions. The report is valuable in highlighting business performance, operating segments, product portfolio, and strategic moves of market players to showcase the competitive scenario.

Recent Development:

• In March 2023, National Hemophilia Foundation launched a venture philanthropy fund named ‘Pathway to Cures’ to drive the development of transformational therapies and technologies for inheritable blood disorders.
• In July 2022, HORIBA, Ltd. rolled out new products in its Yumizen H500 and H550 hematology product family with increased benefits, new features, and enhanced performance.
• In February 2022, Sysmex Corporation established a new arm, Sysmex LLC, in Saudi Arabia with an aim to reinforce its sales and services structure in the country. The new subsidiary would focus on strengthening its hematology, hemostasis, and urinalysis markets.
• In August 2021, rHEALTH in partnership with a global biopharmaceutical company developed a highly accurate, fingerstick-based approach to measure thrombocytopenia (low platelet counts) .

𝐏𝐮𝐫𝐜𝐡𝐚𝐬𝐞 𝐭𝐡𝐞 𝐑𝐞𝐩𝐨𝐫𝐭: https://www.alliedmarketresearch.com/purchase-enquiry/A323977

Our Market Research Solution Provides You Answer to Below Mentioned Question:

• Which are the driving factors responsible for the growth of market?
• Which are the roadblock factors of this market?
• What are the new opportunities, by which market will grow in coming years?
• What are the trends of this market?
• Which are main factors responsible for new product launch?
• How big is the global & regional market in terms of revenue, sales and production?
• How far will the market grow in forecast period in terms of revenue, sales and production?
• Which region is dominating the global market and what are the market shares of each region in the overall market in 2022?
• How will each segment grow over the forecast period and how much revenue will these segments account for in 2030?
• Which region has more opportunities?

By Region Outlook

• North America
(U.S., Canada, Mexico)
• Europe
(Germany, France, UK, Italy, Spain, Rest of Europe)
• Asia-Pacific
(Japan, China, India, Rest of Asia-Pacific)
• LAMEA
(Brazil, Saudi Arabia, South Africa, Rest of LAMEA)

Contact Details:

David Correa
USA/Canada (Toll-Free): +1-800-792-5285, +1-503-894-6022
help@alliedmarketresearch.com

About Us

Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of “Market Research Reports” and “Business Intelligence Solutions.” AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.

David Correa
Allied Market Research
+1 800-792-5285
email us here
Visit us on social media:
Facebook
X

¹ https://www.alliedmarketresearch.com/bleeding-disorders-testing-market-A323977